27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Gemini Therapeutics Inc (NASDAQ:GMTX) and privately held Disc Medicine Inc have entered into a merger agreement in an all-stock transaction.
- The combined company will focus on advancing Disc's pipeline of hematology programs, including multiple patient studies for its clinical-stage programs bitopertin and DISC-0974.
- The combined company will operate under the Disc Medicine moniker, trade on Nasdaq Global Market under the 'IRON' ticker, and be led by Disc Medicine's CEO, John Quisel.
- Also Read: Gemini Axes Chief Scientific Officer, 20% Of Staff To Focus On Geographic Atrophy Candidate.
- A syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture, 5AM Ventures, Novo Holdings A/S, Arix Bioscience, Rock Springs Capital, and Janus Henderson Investors will provide $53.5 million financing to Disc.
- The combined company is expected to have approximately $175 million of cash or cash equivalents.
- The cash resources will be used to advance Disc's pipeline through multiple clinical studies and provide runway into 2025.
- The merger is expected to close in Q4 of 2022.
- Price Action: GMTX shares are down 8.97% at $1.42 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!